title: Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
abstract: Many ErbB2-positive cancers may show intrinsic resistance, and the frequent development of acquired resistance to ErbB-targeted agents represents a substantial clinical problem. The constitutive NF-κB activation in some HER-2/neu positive breast cancer may represent a potential cause of resistance to trastuzumab therapy. Preclinical data revealed that 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the tobacco-specific nitrosamine is able to enhance NF-κB DNA binding activity and theoretically to increase the resistance to trastuzumab. Two hundred and forty-eight women with pathologically confirmed, uni- or bidimensionally measurable, HER-2-positive metastatic breast cancer (MBC) treated with trastuzumab-based therapy as first line combination for metastatic disease were considered eligible. For all included patients data on smoking habit were detectable from medical records. We retrospectively analysed the smoking habits of 248 MBC patients and correlated these habits with activity and efficacy of trastuzumab-based therapy. No statistically significant difference in terms of response rate (RR), time to progression (TTP) and overall survival (OS) was identified between smokers (former plus active smokers) and never smokers. Moreover, no statistically significant difference in terms of RR, TTP and OS was identified either comparing active smokers and former smokers. Moreover, we did not observed any significant statistical difference in terms of TTP and OS between smokers ≥10 cigarettes/day and <10 cigarettes/day. This study clearly showed lack of any correlation between cigarette smoking habit and both activity and efficacy of trastuzumab-based first line therapy in metastatic HER2/neu positive breast cancer patients.
authors: Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
authors: Daniele
authors: D
authors: Santini
authors: Bruno
authors: B
authors: Vincenzi
authors: Vincenzo
authors: V
authors: Adamo
authors: Raffaele
authors: R
authors: Addeo
authors: Vittorio
authors: V
authors: Fusco
authors: Antonio
authors: A
authors: Russo
authors: Filippo
authors: F
authors: Montemurro
authors: Ilaria
authors: I
authors: Roato
authors: Stefania
authors: S
authors: Redana
authors: Gaetano
authors: G
authors: Lanzetta
authors: Maria Antonietta
authors: MA
authors: Satolli
authors: Alfredo
authors: A
authors: Berruti
authors: Valentina
authors: V
authors: Leoni
authors: Sara
authors: S
authors: Galluzzo
authors: Mauro
authors: M
authors: Antimi
authors: Giuseppa
authors: G
authors: Ferraro
authors: Maura
authors: M
authors: Rossi
authors: Salvatore
authors: S
authors: Del Prete
authors: Maria Rosaria
authors: MR
authors: Valerio
authors: Monica
authors: M
authors: Marra
authors: Michele
authors: M
authors: Caraglia
authors: Giuseppe
authors: G
authors: Tonini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000401:mortality; D015331:Cohort Studies; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012907:Smoking / Q000009:adverse effects*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab